Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2020-09-04

Original market date: See footnote 1

2020-09-04

Product name:

CABLIVI

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02496194

Product Monograph/Veterinary Labelling:

Date: 2020-02-28 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

SANOFI-AVENTIS CANADA INC
2905 Place Louis-R. Renaud
Laval
Quebec
Canada  H7V 0A3

Class: 

Human

Dosage form(s):

Powder For Solution,  Kit

Route(s) of administration:

Intravenous,  Subcutaneous

Number of active ingredient(s):

1

Schedule(s):

Schedule D,  Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

20:12.92   ANTITHROMBOTIC AGENTS, MISC.

Anatomical Therapeutic Chemical (ATC): See footnote 4

B01AX07  CAPLACIZUMAB

Active ingredient group (AIG) number:See footnote 5

0162033001

List of active ingredient(s)
Active ingredient(s) Strength
CAPLACIZUMAB 11 MG / VIAL

Application information

Related information

Contact us

Version 3.7.4
Date modified: